SUNNYVALE, Calif., April 24, 2019 /PRNewswire/ -- Accuray
Incorporated (NASDAQ: ARAY) announced today the launch of its
Synchrony® motion tracking and correction
technology1 to be used with the
Radixact® System. This new feature adds intrafraction
motion synchronization capabilities to the Radixact System,
enabling real-time tracking, visualization and correction for tumor
motion during treatment, with the goal of improving dose accuracy
and treatment times compared to conventional radiation therapy
systems. Clinicians attending the European Society for Radiotherapy
& Oncology (ESTRO) meeting are invited to help celebrate the
unveiling of the Radixact System with Synchrony on Friday, April 26, 2019 at 8:00 pm at Accuray booth #800.
Originally developed to expand on the CyberKnife®
System's unique automatic motion tracking and correction
capabilities, Synchrony is the only technology that uses continual
image guidance to automatically adjust the movement of the beam in
synchronization with the movement of the target volume. Synchrony
for the Radixact System is designed to correct for tumors that move
as a result of bodily processes, including respiration and
digestion, as well as patient movement, and has the capability to
perform fiducial-free tracking for lung indications.
The Radixact System is equipped with a built-in CT scanner that
performs daily imaging before each treatment session, providing
clinicians with information on the shape and position of the tumor
and making it possible for them to identify and correct for any
variations in patient positioning. Clinicians are then able to use
Synchrony to automatically synchronize radiation treatment delivery
to the moving tumor's location throughout the treatment session.
This functionality is designed to provide highly precise radiation
dose delivery to tumors that move, such as lung and prostate, and
smaller treatment margins around the tumor, minimizing the
amount of healthy tissue exposed to high-dose radiation.
"Adding the Synchrony motion tracking and correction feature to
our Radixact System is the natural next step on the system's
product development roadmap. Accuray is committed to delivering
product improvements that enable clinicians to optimize their
experience and use of our technology long-term," said Birgit Fleurent, Chief Marketing Officer at
Accuray. "We expect to begin shipping the Synchrony technology
commercially by the end of calendar year 2019."
Jennifer Smilowitz, PhD, clinical
professor University of Wisconsin School of
Medicine and Public Health, and Fellow of the American
Association of Physicists in Medicine (AAPM), has been involved in
the development of the Radixact System from its start. She
comments, "The introduction of Synchrony for this system will
enable clinicians to more easily, and efficiently, deliver precise
radiation treatments to tumors that move using image-guided,
intensity-modulated radiation therapy (IG-IMRT) with target
tracking. In my opinion, this has the potential to expand the way
the Radixact System is used, as well as the types of patients who
are treated with it."
Important Safety Information
For Important Safety Information please refer to
https://www.accuray.com/safety-statement.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) develops, manufactures and
sells radiotherapy systems that are intended to make cancer
treatments shorter, safer, personalized and more effective,
ultimately enabling patients to live longer, better lives. Our
radiation treatment delivery systems in combination with
fully-integrated software solutions set the industry standard for
precision and cover the full range of radiation therapy and
radiosurgery procedures. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, the expected
timing for shipping the Synchrony technology commercially, and the
ability of new product improvements to expand on the use of the
Radixact® System as well as the type of patients treated
with it. These forward-looking statements involve risks and
uncertainties. If any of these risks or uncertainties materialize,
or if any of the company's assumptions prove incorrect, actual
results could differ materially from the results expressed or
implied by these forward-looking statements. These risks and
uncertainties include, but are not limited to, the company's
ability to achieve widespread market acceptance of its products,
including new product offerings and improvements; the company's
ability to develop new products or improve existing products to
meet customers' needs; the company's limited long-term clinical
data supporting the safety and efficacy of its products, including
product improvements, for certain users and such other risks
identified under the heading "Risk Factors" in the company's
quarterly report on Form 10-Q, filed with the Securities and
Exchange Commission (the "SEC") on February
8, 2019 and as updated periodically with the company's other
filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
Media Contacts
Beth
Kaplan
Public Relations Director,
Accuray
+1 (408)
789-4426
bkaplan@accuray.com
Jayme Maniatis
MSLGROUP
+1 (781) 684-6610
accuray@mslgroup.com
1 "Synchrony® Motion Tracking and
Correction Technology" is synonymous with the development name:
"Motion Tracking and Compensation Feature for the
Radixact® Treatment Delivery System"
View original content to download
multimedia:http://www.prnewswire.com/news-releases/accuray-launches-synchrony-motion-tracking-and-correction-technology-for-the-radixact-system-300836858.html
SOURCE Accuray Incorporated